Primecap Management Co. CA Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Posted by Brenda Bartman on Aug 26th, 2026

Primecap Management Co. CA acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,816,680 shares of the medical equipment provider’s stock, valued at approximately $328,578,000. Primecap Management Co. CA owned about 2.00% of Zimmer Biomet as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC bought a new position in Zimmer Biomet in the fourth quarter worth approximately $204,000. Sivia Capital Partners LLC purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth $232,000. United Bank grew its position in shares of Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after acquiring an additional 1,153 shares during the period. Federated Hermes Inc. increased its stake in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC increased its stake in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after purchasing an additional 37,116 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $100.25 on Wednesday. The company has a market cap of $19.12 billion, a P/E ratio of 24.39, a P/E/G ratio of 2.75 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The firm’s fifty day moving average is $93.11 and its two-hundred day moving average is $91.22.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the company posted $2.07 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of analyst reports. Citizens Jmp lowered their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Citigroup decreased their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Canaccord Genuity Group lifted their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. BMO Capital Markets reiterated a “market perform” rating and issued a $96.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Wells Fargo & Company reduced their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $104.42.

Read Our Latest Report on Zimmer Biomet

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.